Oncocross Co., Ltd. (KOSDAQ:382150)
South Korea · Delayed Price · Currency is KRW 12,330
+110 (0.90%)
Dec 10, 2025, 3:30 PM KST
Oncocross Revenue
Oncocross had revenue of 29.18M KRW in the quarter ending September 30, 2025, a decrease of -84.03%. This brings the company's revenue in the last twelve months to 884.68M, up 103.05% year-over-year. In the year 2024, Oncocross had annual revenue of 1.07B with 1,071.49% growth.
Revenue (ttm)
884.68M
Revenue Growth
+103.05%
P/S Ratio
166.00
Revenue / Employee
n/a
Employees
n/a
Market Cap
146.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.07B | 980.68M | 1,071.49% |
| Dec 31, 2023 | 91.52M | -58.72M | -39.08% |
| Dec 31, 2022 | 150.25M | 50.25M | 50.25% |
| Dec 31, 2021 | 100.00M | 10.00M | 11.11% |
| Dec 31, 2020 | 90.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |